TP53 and urinary bladder carcinoma: Regarding bladder cancer, for which cisplatin-based chemotherapy is among the most common regimens for treatment, it was shown that methylation of the promoter of p73, a homolog of p53, was associated with worse overall survival for patients receiving cisplatin-based chemotherapy, and it was therefore suggested that p73 promoter hypermethylation might be used as a prognostic indicator for the cisplatin response in bladder cancer patients [85].